Financial Performance - The company's operating revenue for 2022 was ¥255,467,987.43, a decrease of 10.57% compared to ¥285,655,932.11 in 2021[22]. - The net profit attributable to shareholders for 2022 was ¥40,723,025.38, down 21.72% from ¥52,019,092.21 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was ¥33,633,860.81, a decline of 25.25% from ¥44,997,813.13 in 2021[22]. - The basic earnings per share for 2022 were ¥0.5259, a decrease of 38.73% from ¥0.8584 in 2021[22]. - The company's total revenue for 2022 was ¥255,467,987.43, a decrease of 10.57% compared to ¥285,655,932.11 in 2021[72]. - The net profit attributable to shareholders was ¥40,723,025.38, down 21.72% from the previous year[72]. - The main pharmaceutical business contributed ¥255,397,667.63, accounting for 99.97% of total revenue, with a decrease of 10.43% from the previous year[74]. - The revenue from compound ferrous sulfate tablets was ¥127,441,382.47, representing 49.89% of total revenue, down 15.97% from ¥151,656,589.29[74]. - The revenue from risperidone orally disintegrating tablets was ¥86,789,150.47, which increased by 1.15% compared to the previous year[74]. - The revenue from escitalopram oxalate tablets rose by 31.87% to ¥11,452,434.97, compared to ¥8,684,359.79 in 2021[74]. Dividend Distribution - The company plans to distribute a cash dividend of 1.60 RMB per 10 shares to all shareholders, based on a total of 80,803,943 shares[3]. - The cash dividend proposed is CNY 1.60 per 10 shares, totaling CNY 12,928,630.88, which represents 100% of the profit distribution[161][163]. - The company maintains a stable and active profit distribution policy, prioritizing cash dividends while considering sustainable development[160]. Market Overview - The global pharmaceutical market size was $1,387.5 billion in 2021 and is expected to reach $1,681.6 billion by 2025, with a CAGR of 5.4%[32]. - The Chinese pharmaceutical market size was ¥1,650.1 billion in 2021, projected to grow to ¥2,287.3 billion by 2025, reflecting a CAGR of 9.3%[34]. - The chemical drug market in China reached ¥846.6 billion in 2021 and is anticipated to grow to ¥1,143.8 billion by 2030[35]. - The market for anti-anemia drugs in China was valued at ¥26.45 billion in 2021, showing a year-on-year growth of 2%[40]. Product Performance - The company's core product, Yiyuan Sheng, ranked sixth in the top ten iron supplement products in Chinese urban pharmacies, with a market share of 5.6%[43]. - The online pharmacy market for iron supplements saw Yiyuan Sheng ranked fifth, with a growth rate of 98.86%[43]. - The company holds over 90% market share in the risperidone orally disintegrating tablet market in China, with three manufacturers approved for production[44]. - The company’s product Yiyuan Sheng is positioned in the oral solid dosage form for treating iron deficiency anemia, indicating stable growth prospects[43]. Research and Development - Research and development investment amounted to ¥11,742,523.72, a reduction of 11.80% year-on-year[72]. - The company has increased its R&D personnel by 4.17% to 50, with a higher proportion of bachelor's degree holders rising to 60%[85]. - The company is actively involved in the development of new drugs, particularly in the fields of cardiovascular and anti-tumor medications, to expand its product offerings[59]. - The company is focusing on the industrialization of new products, including the development of Iron Protein Succinate and its oral liquid[84]. Regulatory Environment - The company highlights risks including concentrated core product risks, policy risks from pharmaceutical system reforms, market competition risks, and fluctuations in the supply and prices of raw materials[3]. - The implementation of the DRG/DIP payment reform is expected to promote refined management in hospitals and control healthcare costs[50]. - The revised Drug Administration Law encourages the development of pediatric and rare disease drugs, providing market exclusivity for new pediatric formulations[51]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[171]. - The company has implemented measures to manage waste emissions, including waste gas, wastewater, and noise[171]. - The company has received multiple environmental impact report approvals for projects including solid preparation workshop capacity expansion and raw material drug production[172]. - The company has implemented measures to monitor and control wastewater emissions to meet environmental standards[174]. Corporate Governance - The company has established a comprehensive governance structure in compliance with relevant laws and regulations, enhancing operational standards and governance levels[126]. - The company has a fully independent financial accounting system, enabling it to make autonomous financial decisions without shared bank accounts with controlling entities[131]. - The company has a diverse board with members having backgrounds in engineering, pharmacy, and finance, enhancing its governance structure[138]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 10% to 1.32 billion yuan, driven by new product launches and market expansion strategies[142]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by 2025[142]. - The company aims to improve operational efficiency, targeting a 5% reduction in production costs by implementing advanced manufacturing technologies[142]. - The company is committed to sustainability, with plans to reduce carbon emissions by 30% by 2025 through eco-friendly practices[142].

吉林省西点药业科技发展股份有限公司 2022 年第三季度报告 证券代码：301130 证券简称：西点药业 公告编号：2022-033 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 吉林省西点药业科技发展股份有限公司 2022 年第三季度报告 一、主要财务数据 吉林省西点药业科技发展股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 67,589,032.6 ...

Financial Performance - The company's revenue for the first half of 2022 was CNY 116,625,075.79, a decrease of 14.31% compared to CNY 136,103,664.27 in the same period last year[25]. - Net profit attributable to shareholders was CNY 20,735,846.86, down 10.17% from CNY 23,082,387.99 year-on-year[25]. - Basic earnings per share decreased by 26.52% to CNY 0.2799 from CNY 0.3809 in the same period last year[25]. - The company's operating revenue for the reporting period was ¥116,625,075.79, a decrease of 14.31% compared to ¥136,103,664.27 in the same period last year, primarily due to the impact of the COVID-19 outbreak in Jilin province[62]. - The company's operating costs decreased by 5.63% to ¥20,603,777.07 from ¥21,831,895.60, reflecting the decline in operating revenue[62]. - Research and development expenses dropped significantly by 63.14% to ¥2,896,216.66 from ¥7,856,797.14, due to delays in R&D activities caused by the pandemic[62]. - The net profit attributable to the parent company for the first half of 2022 was CNY 20,735,846.86, a decrease of 10.0% compared to CNY 23,082,387.99 in the same period of 2021[175]. - The basic and diluted earnings per share for the first half of 2022 were CNY 0.2799, down from CNY 0.3809 in the first half of 2021, reflecting a decline of 26.5%[175]. Cash Flow and Investments - The net cash flow from operating activities increased by 47.98% to CNY 34,600,350.11 from CNY 23,381,179.34 in the previous year[25]. - The net cash flow from financing activities surged to ¥382,329,257.51, a dramatic increase of 6,113,504.45% compared to -¥6,253.95, due to funds raised from the initial public offering[62]. - The company's cash and cash equivalents increased by 197.84% to ¥45,592,863.60 from ¥15,308,026.25, primarily due to the funds raised from the IPO[62]. - The company reported cash inflow from investment activities of CNY 65,486,573.97, while cash outflow was CNY 436,823,317.99, resulting in a net cash outflow of CNY 371,336,744.02[177]. - The total amount of funds raised through the initial public offering was CNY 455,532,200, with a net amount of CNY 390,933,100 after deducting various issuance costs[79]. - The company has cumulatively used CNY 613,500 of the raised funds, leaving a balance of CNY 378,302,700, including interest generated from the raised funds[79]. Assets and Liabilities - Total assets increased by 66.63% to CNY 990,776,059.11 from CNY 594,606,181.26 at the end of the previous year[26]. - Net assets attributable to shareholders rose by 76.54% to CNY 925,302,447.81 from CNY 524,138,056.37 at the end of the previous year[26]. - The company's total liabilities decreased to CNY 65,473,611.30 from CNY 70,468,124.89, a reduction of 7.1%[172]. - Shareholders' equity rose to CNY 925,302,447.81 as of June 30, 2022, up from CNY 524,138,056.37 at the beginning of the year, reflecting a growth of 76.5%[172]. Market and Product Development - The company is focused on the development of new drugs and technologies, although specific details are not provided in the excerpts[14]. - The company has 22 registered formulation varieties and 16 registered raw material drug varieties, focusing on anemia treatment and mental disorder medications[38]. - The company’s core product in the anemia treatment market had a market size of CNY 26.45 billion in 2021, showing a year-on-year growth of 2%[42]. - The top ten brands in the anemia treatment market hold approximately 73% market share, with key products including Hongyuanda, Sentieneng, and the company's Yiyuan Sheng[43]. - The company is actively pursuing new product development and quality standard enhancements to maintain its market position and expand its product offerings[52]. Risk Management - The company emphasizes the importance of investors being aware of potential risks and challenges in its operations[3]. - The report includes a section on risks and countermeasures, which is crucial for investor awareness[3]. - The company faces risks from medical system reforms, which may increase operational costs and affect business performance if not adapted to timely[90]. - The ongoing COVID-19 pandemic has impacted production and sales, particularly affecting the sales of its main product, a treatment for anemia[91]. - Fluctuations in raw material prices pose a risk to the company's production costs and profit margins[94]. Corporate Governance and Compliance - The financial report is guaranteed to be true, accurate, and complete by the company's management, including the chairman and accounting heads[3]. - The company has continuously improved its governance structure to protect the rights of investors[111]. - The company has not experienced any major litigation or arbitration matters during the reporting period[125]. - The company has not engaged in any related party transactions during the reporting period[126]. - The company has maintained compliance with environmental regulations, with no major environmental accidents reported during the reporting period[110]. Environmental Management - The company has implemented effective management of wastewater, waste gas, solid waste, and noise pollution, ensuring compliance with environmental regulations[105]. - The company employs noise reduction measures, including sound insulation and vibration reduction, to minimize operational noise[105]. - The company has invested in various environmental protection equipment, ensuring normal operation of its environmental facilities[109]. - The company has established a comprehensive quality assurance system to protect consumer rights and ensure high-quality products[115]. Shareholder Information - The total number of shares increased from 60,602,957 to 61,644,401 due to the issuance of new shares[146]. - The company has a diverse shareholder base, with both individual and institutional investors represented[156]. - The total number of common shareholders at the end of the reporting period is 18,853[154]. - Zhang Jun, a domestic individual, holds 24.29% of the shares, totaling 19,627,034 shares[154]. - The company has not reported any share buyback activities or changes in restricted shares during the reporting period[150].

Financial Performance - The company's revenue for Q1 2022 was ¥53,106,464.55, a decrease of 14.66% compared to ¥62,227,442.74 in the same period last year[3] - Net profit attributable to shareholders was ¥7,906,004.78, down 25.22% from ¥10,572,246.52 year-on-year[3] - Basic and diluted earnings per share were both ¥0.1174, reflecting a decrease of 32.72% from ¥0.1745 in the same period last year[3] - Total operating revenue for Q1 2022 was CNY 53,106,464.55, a decrease of 14.5% compared to CNY 62,227,442.74 in the same period last year[22] - Net profit for Q1 2022 was CNY 7,906,004.78, representing a decline of 25.3% from CNY 10,572,246.52 in Q1 2021[24] - Earnings per share for Q1 2022 was CNY 0.1174, down from CNY 0.1745 in the previous year[25] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly to ¥15,610,919.58, a 683.96% improvement from -¥2,673,267.98 in the previous year[3] - The company's cash and cash equivalents amounted to RMB 637,637,486.24, up from RMB 148,630,019.72 at the beginning of the year, reflecting a substantial growth in liquidity[19] - The net cash flow from operating activities was 15,610,919.58 CNY, a significant improvement compared to -2,673,267.98 CNY in the previous year[28] - The net cash flow from investing activities was 64,048,790.21 CNY, recovering from a negative cash flow of -1,884,270.00 CNY in the same period last year[28] - The net cash flow from financing activities amounted to 409,347,756.73 CNY, indicating strong capital inflow[29] - The total cash and cash equivalents at the end of the period reached 637,080,557.42 CNY, up from 102,623,538.74 CNY year-over-year[29] - The cash flow from operating activities showed a positive trend, indicating improved operational efficiency[28] Assets and Equity - Total assets at the end of the reporting period reached ¥1,002,392,131.32, representing a 68.58% increase from ¥594,606,181.26 at the end of the previous year[3] - Shareholders' equity attributable to the company was ¥922,977,118.32, up 76.09% from ¥524,138,056.37 at the end of the last year[3] - The total current assets increased to RMB 725,917,369.13 from RMB 314,929,356.70, showcasing a strong improvement in the company's short-term financial position[20] - The total non-current assets decreased slightly to RMB 276,474,762.19 from RMB 279,676,824.56, suggesting stability in long-term investments[20] - Total equity attributable to shareholders increased to CNY 922,977,118.32 from CNY 524,138,056.37, a significant rise of 76.1%[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,577[10] - The company has issued a total of 20,200,986 shares in its initial public offering, which was approved by the China Securities Regulatory Commission[17] Operational Highlights - The company plans to continue its market expansion and product development strategies, aiming for sustainable growth in the upcoming quarters[17] - The company is focusing on research and development of new products and technologies to enhance its competitive edge in the pharmaceutical industry[17] Donations and Subsidies - The company received government subsidies amounting to ¥770,553.18, which are closely related to its normal business operations[6] - The company made a donation of ¥1,000,000 to the Red Cross Society of Panshi City for epidemic prevention support[6] Other Financial Metrics - Total operating costs for Q1 2022 were CNY 44,475,693.43, down 14.4% from CNY 51,939,691.57 year-on-year[22] - Accounts payable increased to CNY 8,386,126.64 from CNY 6,235,531.98, reflecting a rise of 34.5%[21] - Other payables rose to CNY 27,186,912.80 from CNY 18,852,139.04, marking an increase of 43.8%[21] - Total liabilities amounted to CNY 79,415,013.00, up from CNY 70,468,124.89, indicating a growth of 12.8%[21] - Deferred income decreased slightly to CNY 35,008,213.57 from CNY 35,778,766.75, a decline of 2.1%[21] - The report for the first quarter was not audited, which may affect the reliability of the financial data presented[30]

Financial Performance - The company's operating revenue for 2021 was ¥285,655,932.11, a decrease of 0.23% compared to ¥286,318,719.28 in 2020[20]. - The net profit attributable to shareholders for 2021 was ¥52,019,092.21, representing an increase of 4.58% from ¥49,742,435.47 in 2020[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥44,997,813.13, up 6.06% from ¥42,427,354.94 in 2020[20]. - The net cash flow from operating activities for 2021 was ¥59,013,817.04, a decline of 8.56% compared to ¥64,541,781.89 in 2020[20]. - The total assets at the end of 2021 were ¥594,606,181.26, an increase of 7.96% from ¥550,760,343.90 at the end of 2020[20]. - The net assets attributable to shareholders at the end of 2021 were ¥524,138,056.37, reflecting an increase of 11.02% from ¥472,118,964.16 at the end of 2020[20]. - The basic earnings per share for 2021 were ¥0.8584, up 4.58% from ¥0.8208 in 2020[20]. - The diluted earnings per share for 2021 were also ¥0.8584, consistent with the basic earnings per share[20]. - The weighted average return on equity for 2021 was 10.44%, a decrease of 0.48% from 10.92% in 2020[20]. - The gross profit margin for the main pharmaceutical business was 83.67%, a decrease of 1.02% year-on-year[92]. - The company's main business revenue reached CNY 285.14 million, with a slight increase of 0.12% compared to the same period last year[92]. Dividend and Profit Distribution - The company reported a cash dividend of 1.30 RMB per 10 shares, totaling approximately 10.5 million RMB for all shareholders[6]. - The company implemented a stable profit distribution policy, prioritizing cash dividends, with a total cash dividend amounting to ¥10,504,512.59, which is 100% of the distributable profit[184][187]. - For the fiscal year 2021, the company achieved a net profit of ¥52,019,092.21[186]. - The cash dividend per 10 shares is set at ¥1.30 (including tax), based on a total share capital of 80,803,943 shares[187]. - The total distributable profit as of December 31, 2021, was ¥317,064,302.68[187]. - There were no stock dividends or capital increases from capital reserves during the reporting period[184][187]. Market and Industry Trends - The Chinese pharmaceutical market is projected to reach ¥17.29 billion in 2021, reflecting a recovery and growth trend post-pandemic[35]. - The company has identified significant growth opportunities in the pharmaceutical sector due to increasing healthcare spending and an aging population in China[38]. - The global pharmaceutical market is expected to continue growing, driven by population growth and aging demographics, with China being a key emerging market[31]. - The COVID-19 pandemic has significantly increased public awareness of diseases and health, potentially boosting pharmaceutical sales and improving treatment adherence for conditions like depression[40]. - The rise of internet healthcare channels since 2020 has enhanced drug accessibility, leading to a digital transformation in the pharmaceutical industry, which is expected to drive growth in chronic disease treatment[40]. - The pharmaceutical industry has high entry barriers due to strict regulatory oversight, ensuring orderly development and market access[41]. - The industry is characterized by high investment, high output, and high technology density, with significant government support for innovation and transformation[42]. Product Development and Innovation - The company is actively developing new products, including Ferrous Fumarate and Calcium Citrate, with ongoing quality standard enhancements and industrialization efforts[78]. - The company has a robust innovation-driven development strategy, continuously enhancing its technological capabilities and maintaining profitability over the years[54]. - The company has established a strong integrated advantage in "raw materials + formulations" after years of differentiated development[60]. - The company is committed to developing high-value-added products and promoting the scale and intensive development of the raw material drug industry over the next five years[59]. - The company has completed significant research on the quality standards of starting materials and is working on the industrialization of new products[104]. Risks and Challenges - The company highlighted risks including product concentration, policy changes due to pharmaceutical reforms, market competition, and operational risks from the COVID-19 pandemic[6]. - The company faces policy risks due to ongoing medical system reforms that may increase operational costs and alter business models[131]. - Environmental protection pressures may lead to increased costs and risks if the company fails to comply with national standards[134]. - The company relies on approved suppliers for raw materials, and any disruptions in supply could adversely affect production[134]. - The pharmaceutical industry is experiencing intensified internal competition, with more domestic and international companies entering the market, leading to a decline in average profit margins[136]. Corporate Governance - The company has established a comprehensive corporate governance structure in compliance with relevant laws and regulations, ensuring proper operational management[139]. - The company held one shareholders' meeting during the reporting period, adhering to all legal and procedural requirements[140]. - The board of directors consists of nine members, including three independent directors, meeting the legal requirements for composition[142]. - The supervisory board is composed of five members, ensuring compliance with legal and regulatory standards[143]. - The company emphasizes the importance of information disclosure and investor relations management, with a detailed management system in place[147]. Environmental Compliance - The company has implemented effective measures for wastewater treatment, with a treatment capacity of 200 cubic meters per day, ensuring compliance with environmental standards[196]. - The company utilizes high-efficiency dust removal systems with a removal rate of 90% for particulate matter and 95% for volatile organic compounds[196]. - All hazardous waste is managed properly, with 100% of hazardous waste being disposed of by a licensed environmental service provider[197]. - The company adheres to national environmental protection laws and regulations, ensuring that all pollutants are discharged in compliance with relevant standards[198]. - The company has established a robust internal control system, with the audit report aligning with the board's self-evaluation[192].